Table 4 Long term results of current studies on SBRT for liver metastases
Author, (reference) design study, year | Patients with liver metastases | Dose (Gy/ fr) | Follow-up (median) | Local control (%) | Overall survivall (%) | Toxicity ≥G3 | ||
|---|---|---|---|---|---|---|---|---|
1-year | 5-yeras | 1-year | 5-years | |||||
Hoyer, [15] Phase II, 2006 | 44 | 45Gy/3fr | 4.3 years | 79% at 2 years | – | 67% | 13% | 48% |
Fode, [18] Retrospective. 2015 | 212 (321 tot oligometastatic patient) | BED10 = 72–195 Gy | 5 years | 91% | – | 80% | 23% | 4% |
(Not specified for liver metastases) | (Not specified for liver metastases) | |||||||
Goodman, [39] Retrospective 2016 | 81 | 32–60/3–5 fr | 2.25 years | 96% | 91% at 4 years | 89.9% | 28% at 4 years | 4.9% |
McPartlin, [28] Phase I-II, 2017 | 51 | 22.7–62.1 Gy /6 fr | 2.3 years | 49.8% | 26% at 4 years | 63% | 9% at 4 years | 3% |
Joo, [29] Retrospective 2017 | 70 | 45-60Gy/3–4fr | 2.8 years | 93% | 68% at 3 years | 75% at 2 years | 0% | |
Mendez Romero [40] Retrospective, 2017 | 40 | 37.5 Gy / 3fr | 2.2 years | 96% | 66% at 3 years | 95% | 48% at 3 years | 7.5% |
50.25 Gy / 3 fr | 90% | 81% at 3 years | 94% | 65% at 3 years | ||||
Present study | 61 | 75Gy/3 fr (82% of lesions) 67.5–52.5 Gy/3fr (18% of lesions) | 6.1 years | 94% | 78% | 85.2% | 18% | 1% |